George D. Yancopoulos;Nicholas J. Papadopoulos;David J. GLASS;Thomas J. Daly
发明人:
David J. GLASS,George D. Yancopoulos,Thomas J. Daly,Nicholas J. Papadopoulos
申请号：
US13416481
公开号：
US20120195896A1
申请日:
2012.03.09
申请国别(地区):
US
年份:
2012
代理人:
摘要：
A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
